Oct 06, 2023 / 01:00AM GMT
Presentation
Oct 06, 2023 / 01:00AM GMT
=====================
Corporate Participants
=====================
* Thomas Duthy
Neurotech International Ltd - Executive Director
=====================
Thomas Duthy - Neurotech International Ltd - Executive Director
Good afternoon, everyone, and thank you for joining Neurotech International today. It's my pleasure to present to you a summary of the company's Phase I/II clinical trial results for a broad-spectrum of cannabinoid drug product, NTI164, in children with paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, PANDAS, and Paediatric Acute-Onset Neuropsychiatric Syndrome, PANS; collectively, PANDAS/PANS. I trust all of you on today's call had a chance to read the announcement that was launched about six this morning. And shortly thereafter, investor presentation, which summarizes the key findings of this world-first trial.
Before I commence today's presentation, I would like to express my sincere thanks to Professor Russell Dale and Professor Michael Fahey, the
Neurotech International Ltd Phase I/II PANDAS/PANS Clinical Trial Results Presentation Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot